Bruger:Bob Collowân/Værksted 1: Forskelle mellem versioner
Content deleted Content added
Lukket |
Nyt projekt |
||
Linje 1:
'''Remdesivir''' is a [[Broad-spectrum antiviral drug|broad-spectrum]] [[antiviral medication]] developed by the [[biopharmaceutical]] company [[Gilead Sciences]].<ref name="Scavone_2020">{{cite journal | vauthors = Scavone C, Brusco S, Bertini M, Sportiello L, Rafaniello C, Zoccoli A, Berrino L, Racagni G, Rossi F, Capuano A | display-authors = 6 | title = Current pharmacological treatments for COVID-19: what's next? | journal = British Journal of Pharmacology | date = April 2020 | pmid = 32329520 | doi = 10.1111/bph.15072 |doi-access=free }}</ref> As of 2020, remdesivir is being tested as a specific treatment for [[COVID-19]], and has been authorized for emergency use in the U.S. and approved for use in Japan for people with severe symptoms.<ref name="FDA_EUA">{{cite web | title = Remdesivir EUA Letter of Authorization | url = https://www.fda.gov/media/137564/download | format = PDF | website = U.S. [[Food and Drug Administration]] (FDA) | date = 1 May 2020 | access-date = 1 May 2020}} {{PD-notice}}</ref><ref name="FDA EUA PR" /><ref name=":0">{{Cite web|title=Japan approves remdesivir for COVID-19 despite uncertainties|url=http://www.asahi.com/ajw/articles/13358075|website=The Asahi Shimbun|access-date=2020-05-09}}</ref> It may shorten the time it takes to recover from the infection.<ref name="Hopkins"/> Treatment is given by [[intravenous|injection into a vein]].<ref>{{cite web |title=Remdesivir |url=https://www.drugs.com/ppa/remdesivir.html |website=Drugs.com |access-date=30 April 2020}}</ref><ref name="Mehta2020">{{cite journal | vauthors = Mehta N, Mazer-Amirshahi M, Alkindi N | title = Pharmacotherapy in COVID-19; A narrative review for emergency providers | journal = The American Journal of Emergency Medicine | pages = S0735-6757(20)30263-1 | date = April 2020 | pmid = 32336586 | doi = 10.1016/j.ajem.2020.04.035 | pmc = 7158837 | doi-access=free }}</ref>
| |||